Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR1 | P25024 | 1/20 | 0.63 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.63 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | GPR88 | Q9GZN0 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CTSD | P07339 | 1/20 | 0.46 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.45 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ELOVL1 | Q9BW60 | 2/20 | 0.44 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28625698 | 0.83 | CXCR1 (0.66) | CXCR1CXCR2KMT2AGPR88LMNA | |
| SCHEMBL3905518 | 0.82 | CTSD (0.62) | KMT2APOLBCTSDMEN1 | |
| SCHEMBL28622615 | 0.81 | CXCR1 (0.64) | CXCR1CXCR2L3MBTL1PTGS2 | |
| SCHEMBL28711758 | 0.81 | LMNA (0.52) | CXCR1CXCR2KMT2ALMNACTSD | |
| SCHEMBL28711757 | 0.81 | LMNA (0.52) | CXCR1CXCR2KMT2ALMNACTSD | |
| SCHEMBL721905 | 0.80 | GRM7 (0.53) | GRM7KMT2AGPR88LMNAL3MBTL1 | |
| SCHEMBL6266741 | 0.80 | CTSD (0.64) | GRM7GPR88LMNAL3MBTL1POLB | |
| SCHEMBL11776768 | 0.79 | KMT2A (0.48) | CXCR1CXCR2KMT2AL3MBTL1CTSD | |
| SCHEMBL6162055 | 0.79 | KMT2A (0.48) | CXCR1CXCR2KMT2ALMNACTSD | |
| SCHEMBL29278519 | 0.79 | ALDH1A1 (0.56) | CXCR1CXCR2GRM7KMT2AGPR88 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753405-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-12 | — | — | US | disclosed |
| US-20210246131-A1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-08-12 | — | — | US | disclosed |
| EP-2999695-A1 | SOLID FORMS OF FUNGICIDAL PYRAZOLES | E. I. du Pont de Nemours and Company (US) | 2016-03-30 | — | — | EP | disclosed |
| WO-2015157005-A1 | SUBSTITUTED TOLYL FUNGICIDE MIXTURES | E I DU PONT DE NEMOURS AND COMPANY (US) | 2015-10-15 | — | — | WO | disclosed |
| EP-2912020-A1 | SUBSTITUTED TOLYL FUNGICIDES | E. I. du Pont de Nemours and Company (US) | 2015-09-02 | — | — | EP | disclosed |
| EP-2820010-A1 | BENZOFURAN- 2 - SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2015-01-07 | — | — | EP | disclosed |
| EP-2809157-A2 | FUNGICIDAL PYRAZOLE MIXTURES | E. I. Du Pont de Nemours and Company (US) | 2014-12-10 | — | — | EP | disclosed |
| WO-2014130409-A2 | FUNGICIDAL PYRAZOLE MIXTURES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2014-08-28 | — | — | WO | disclosed |
| WO-2014066120-A1 | SUBSTITUTED TOLYL FUNGICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2014-05-01 | — | — | WO | disclosed |
| WO-2013130962-A1 | BENZOFURAN- 2 - SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| WO-2013116251-A2 | FUNGICIDAL PYRAZOLE MIXTURES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2013-08-08 | — | — | WO | disclosed |
| US-6743794-B2 | MULTIDRUG RESISTANCE PROTEIN; CANCER; 3-(9-CHLORO-3-METHYL-4-OXO-5H-ISOXAZOLO(4,3-C)QUINOLIN-5-YL)) CYCLOHEXYL)-2-PIPERIDYLACETAMIDE | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246131-A1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | GLS2, GLS, GLUL | CXCR1 2925/4885CXCR2 4431/4885GRM7 842/4885 |
| US-11753405-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | GLS2, GLS, GLUL | CXCR1 2925/4885CXCR2 4431/4885GRM7 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.